Tryp Therapeutics

Tryp Therapeutics is a clinical-stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.

Tryp Therapeutics

The company is very new and you can find their investor presentation here.

Tryp Therapeutics has raised a total of U$1.58 in funding over 1 round. This was a Post-IPO Equity round raised on Feb 5, 2021. They are registered under the ticker CNSX: TRYP.

Key Staff

  • James Kuo – CEO
  • William Garner – Executive Chairman
  • Jay Campbell – CBO
  • Robin Carhart-Harris – Scientific Advisor


Company Information

Tryp Therapeutics Website

August, 2020


B2B B2C Drug Discovery

Topics of Interest
Fibromyalgia Eating Disorders

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office Kelowna, BC, Canada